Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Ledipasvir/Sofosbuvir in HCV-Infected Children With Hematological Malignancy
NCT03903185Phase 2Completed
- Sponsor
- Ain Shams University
- Start
- Mar 2019
- Primary completion
- Jul 2023
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, open-label trial of Harvoni in hepatitis C (HCV) (2 arms), sponsored by Ain Shams University. Primary endpoint: Pharmacokinetics of Ledipasvir/Sofosbuvir at 10 days. Started Mar 2019; status: completed.
02
Drugs
Harvoni
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03903185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03903185.